pembrolizumab – Page 2

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Squamous-Cell Carcinoma: A Phase 3 Trial Overview and Clinical Implications

By MedXY 08/19/2025

The phase 3 KEYNOTE-689 trial demonstrates that adding perioperative pembrolizumab to surgery and adjuvant therapy significantly improves event-free survival in locally advanced HNSCC without compromising surgical outcomes or safety.

Clinical Updates news Oncology Specialties Urology

KEYNOTE-991: Pembrolizumab Does Not Improve Outcomes in Metastatic Hormone-Sensitive Prostate Cancer—A Phase III Clinical Trial Analysis

By MedXY 08/08/2025

KEYNOTE-991 shows pembrolizumab does not improve progression-free or overall survival for mHSPC, and increases serious adverse events when added to enzalutamide and ADT.

Clinical Updates news Oncology Specialties

LEAP-015: Evaluating Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy Alone in Advanced Gastroesophageal Adenocarcinoma

By MedXY 08/07/2025

The LEAP-015 phase III trial found that adding lenvatinib and pembrolizumab to chemotherapy marginally improved progression-free survival but not overall survival in advanced gastroesophageal adenocarcinoma, with increased toxicity.

Clinical Updates news Oncology Specialties

Timing Matters: Sequential Pembrolizumab Plus Chemoradiation Outperforms Concurrent Approach in Locally Advanced Head and Neck Cancer

By MedXY 08/07/2025

A Phase II trial finds sequential pembrolizumab after chemoradiation achieves superior locoregional control compared to concurrent administration in locally advanced head and neck squamous cell carcinoma.

Clinical Updates news Oncology Specialties Urology

Enfortumab Vedotin Plus Pembrolizumab vs Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Cancer: Patient-Reported Outcomes from the EV-302 Phase 3 Study

By MedXY 08/03/2025

The EV-302 trial shows enfortumab vedotin plus pembrolizumab improves survival and quality of life over platinum-based chemotherapy in untreated advanced urothelial cancer patients.